Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with ۵-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial

سال انتشار: 1390
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 77

فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_MISJ-2-2_002

تاریخ نمایه سازی: 25 آبان 1402

چکیده مقاله:

Background: The present study aimed to compare the rates of complete clinical and pathologic response to docetaxel, doxorubicin and cyclophosphamide (TAC) vs. ۵-fluorouracil, doxorubicin and cyclophosphamide (FAC) as neoadjuvant chemotherapy in women with locally advanced breast cancer. Methods: One hundred women with pathologically confirmed newly diagnosed locally advanced (T۳-T۴ or N۲-N۳) breast cancer were randomly assigned to receive a median of four cycles of either ۵-fluorouracil (۶۰۰ mg/m۲), doxorubicin (۶۰ mg/m۲) and cyclophosphamide (۶۰۰ mg/m۲) every three weeks or docetaxel (۷۵ mg/m۲), doxorubicin (۵۰ mg/m۲) and cyclophosphamide (۵۰۰ mg/m۲) every three weeks followed by modified radical mastectomy. Complete clinical and pathologic response rates and toxicity were the primary and secondary outcome measures of the study.Results: Median age for all patients was ۴۳.۴ years (range ۲۵-۶۳ years). Patients in the TAC arm achieved a higher clinical (۱۶%) response rate than those in the FAC arm (۴%, P=۰.۰۴۶). The pathologic response rate was also higher in the TAC arm compared to the FAC arm [TAC (۲۰%) vs. FAC (۶%), P=۰.۰۳۷]. Estrogen receptor- negative status correlated with a higher clinical [TAC (۱۹%) vs. FAC (۴%), P=۰.۰۳۲] and pathologic [TAC (۲۳%) vs. FAC (۴%), P=۰.۰۱۱)] response rate in both arms. All patients generally tolerated treatment well, and treatment-related toxicities were manageable.Conclusion: Combined treatment with TAC led to higher rates of complete clinical and pathologic response with acceptable toxicity compared to FAC in patients with locally advanced breast cancer. However, further follow-up is needed to translate this response into improvements in survival.

نویسندگان

Shapour Omidvari

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Sare Hosseini

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Yaghoub Ashouri

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Sedigheh Tahmasebi

Department of Surgery, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Abdolrasoul Talei

Department of Surgery, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Hamid Nasrolahi

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Niloofar Ahmadloo

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Mansour Ansari

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Ahmad Mosalaei

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Mohammad Mohammadianpanah

Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran